X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - HEALTHTECHZONE.COM - IT Professionals - 12/Aug 12:30

CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer

Articles similaires

Sorry! Image not available at this time

Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug

zacks.com - 11/Sep 14:47

CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell...

Sorry! Image not available at this time

Merakris Therapeutics Announces FDA Clearance for Part 2 of its Phase II Multicenter Investigational New Drug Study of Dermacyte® Liquid

healthtechzone.com - 05/Sep 10:30

Sorry! Image not available at this time

Merakris Therapeutics Announces FDA Clearance for Part 2 of its Phase II Multicenter Investigational New Drug Study of Dermacyte® Liquid

healthtechzone.com - 05/Sep 10:30

Sorry! Image not available at this time

Data Shows Cell-Free DNA Test Predicts Colorectal Cancer Survival

medindia.net - 00:35

A new GALAXY study reveals Signatera's cell-free DNA test predicts survival rates and chemotherapy benefits for colorectal cancer patients with high...

Sorry! Image not available at this time

Data Shows Cell-Free DNA Test Predicts Colorectal Cancer Survival

medindia.net - 00:35

A new GALAXY study reveals Signatera's cell-free DNA test predicts survival rates and chemotherapy benefits for colorectal cancer patients with high...

Sorry! Image not available at this time

Early, Virtual Palliative Care Feasible for Advanced Lung Cancer

drugs.com - 15:09

TUESDAY, Sept. 17, 2024 -- The delivery of early, virtual palliative care has similar effects on quality of life as in-person care in patients with...

Sorry! Image not available at this time

Omitting 5-FU Bolus Does Not Reduce Survival in Advanced Cancer

drugs.com - 10/Sep 22:20

TUESDAY, Sept. 10, 2024 -- Omission of 5-fluorouracil (5-FU) from the first-line FOLFOX, FOLFIRI, and FOLFIRINOX regimens is not associated with...

Sorry! Image not available at this time

WCLC 2024: NeoCOAST-2 Data shows combination of Durvalumab with novel agents increases pathological responses in resectable NSCLC — Data builds on AEGEAN study research

oncologynews.com.au - 15/Sep 05:24

Phase 2 results from the NeoCOAST-2 study demonstrated that the combination of durvalumab with Dato-DXd yielded the highest pathological complete...

Sorry! Image not available at this time

Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

drugs.com - 03/Sep 01:09

LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...

Sorry! Image not available at this time

New cancer drug shows encouraging results in Phase I/II trial

news.medical.net - 14/Sep 08:17

The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with similar ADCs and initial...

Les derniers communiqués